NEW YORK (GenomeWeb News) – Exact Sciences has raised $57.8 million in net proceeds from its public offering, the Madison, Wis.-based firm announced after the close of the market on Monday.

The company sold a total of 6,325,000 shares of its common stock at $9.75 per share. Jefferies and Co. and R.W. Baird were joint book-running managers in the offering, and William Blair & Co. and JMP Securities were co-managers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.